Potentially addressing
millions of patients / year
Xeltis is currently investigating applications of its innovative approach to restore heart valves and small diameter blood vessels.
Over 25 patients implanted
Restorative small diameter vascular applications, including Coronary Artery Bypass Grafts (CABG) are showing promising results in preclinical trials.
The first few patients receiving Xeltis pediatric vascular grafts have now reached their 5-year follow-up.
Xeltis restorative heart valves have been in trials for years, including two clinical trials in EU, Asia and in the USA.
Xeltis has been recognized as a breakthrough medtech start-up
AWARDED
Gold Testing & Treatment Options at 2017 Edison Awards
INCLUDED
Fierce 15 list by Fierce Medical Devices 2015
NOMINATED
Out-of-the-box technology at PCR 2015
AWARDED
Biovision Next Gem Award 2013
RECOGNIZED
Promising Start-up by IMD Business School
SELECTED
Top-25 Tech-tour Medtech Summit 2012
